#RSVProphylaxe mit #Nirsevimab: Vorteile für gesunde Kinder in der ersten RSV-Saison
Mit dem Antikörper Nirsevimab immunisierte Kinder erkranken deutlich seltener an RSV-bedingten Infektionen der unteren Atemwege.
https://www.iqwig.de/presse/pressemitteilungen/pressemitteilungen-detailseite_148816.html
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #children #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #prevention #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #prevention #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
RaiNews by undefined
Virus sinciziale, da novembre ai neonati l'anticorpo monoclonale. Intesa in stato-regioni
Via libera dalla conferenza Stato-regioni al piano di immunizzazione contro il virus Sinciziale (vrs) per tutti i neonati con l'anticorpo monoclonale Nirsevimab. Sono stati stanziati 50 mln
Translated:
The monoclonal antibody for infants has been available since November to treat respiratory syncytial virus (RSV). An agreement between the government and regions has been reached.
The State-Regions conference has given the green light to the immunization plan against the Syncytial Virus (RSV) for all newborns with the monoclonal antibody Nirsevimab. €50 million have been allocated.
#RSV #Nirsevimab #StateRegions
https://www.rainews.it/articoli/2024/10/da-novembre-ai-neonati-lanticorpo-contro-virus-sinciziale-intesa-in-stato-regioni-ed0c85c0-4620-4f5d-b4c2-1f0cf5a85189.html
Corriere.it - Homepage by di Ruggiero Corcella
Virus respiratorio sinciziale, campagna in ritardo e solo per il 75% dei bambini
Nirsevimab, il nuovo anticorpo monoclonale di Sanofi contro l'infezione nei bambini, sarà disponibile in Italia dal 28 ottobre. Le dosi garantiranno però solo il 75% della copertura di nascite
Translated:
Respiratory syncytial virus, campaign delayed and only for 75% of children.
Nirsevimab, Sanofi's new monoclonal antibody against infection in children, will be available in Italy from October 28th. However, the doses will only guarantee 75% coverage of births.
#Nirsevimab #Sanofi #Italy
https://www.corriere.it/salute/figli-genitori/bambino/24_ottobre_03/virus-respiratorio-sinciziale-la-campagna-di-immunizzazione-con-il-nuovo-farmaco-copriro-parte-in-ritardo-e-coprira-solo-il-75-dei-bambini-interessati-69000122-ddf6-49d3-a0bb-9545db2a9xlk.shtml
Doctor Miguel O’Ryan: “Este año debería quebrarse la tradicional curva crítica de invierno” | #UChileRadio
#migueloryan #movimientoantivacuna #nirsevimab #virusinfluenza #virussincicial
In einem Press Briefing des Science Media Center Germany ordnet unter anderem Thomas Pietschmann, Virologe am HZI & @TWINCORE, die neue STIKO-Empfehlung zur #RSV-Prophylaxe mit #Nirsevimab ein. https://www.sciencemediacenter.de/alle-angebote/press-briefing/details/news/empfehlung-der-staendigen-impfkommission-zur-rsv-immunisierung/
https://www.abc.net.au/news/2024-03-25/qld-rsv-jab-explainer-who-is-eligible/103630628?utm_source=abc_news_app&utm_medium=content_shared&utm_campaign=abc_news_app&utm_content=other “The state government has announced a $31 million program to immunise more than 70,000 newborn babies, eligible infants and young children.
They will be given a #MonoclonalAntibody – or man-made protein – called Nirsevimab, which is marketed as Beyfortus.
Delivered as an injection, #Nirsevimab has been shown to be about 80 per cent effective at preventing young infants from being hospitalised with lower respiratory tract infection, caused by #RSV.”
Der spanische Pädiater Toni Soriano (@tonisoriano66) hat ein paar Informationen zu deren Programm gegen #RSV veröffentlicht.
Babies bekamen #Nirsevimab und waren damit auf eine Infektion vorbereitet. Damit kamen 84% weniger ins Krankenhaus und 87 % weniger Babys unter 6 Monaten auf die Intensivstation.
Das Programm kostete etwa 14 Mio. € und der Krankenhausaufenthalt der Kinder im letzten Jahr kostete etwa 18 Mio. €. Also schon jetzt ein unglaublicher Erfolg.
https://nitter.net/tonisoriano66/status/1735995760133451967?s=20
Inne przeciwciało monoklonalne, nazwane #Nirsevimab opracowane przez AstraZeneca i Sanofi, zakończyło z powodzeniem badania 3 fazy w 2022r.
9/n
